Article Data

  • Views 699
  • Dowloads 151

Reviews

Open Access

Should we search for high-risk HPV in vaginal vault Pap smear after hysterectomy due to CIN2+?

  • I. Ferreira1,*,
  • C. Estevinho2
  • XXX1
  • A. Torgal2
  • C. Carrapatoso2
  • F. Costa2

1Serviço de Ginecologia e Obstetrícia do Centro Hospitalar e Universitário de Coimbra, Coimbra

2Serviço de Ginecologia e Obstetrícia do Centro Hospitalar Tâmega e Sousa, Penafiel (Portugal)

DOI: 10.31083/j.ejgo.2020.02.5226 Vol.41,Issue 2,April 2020 pp.157-162

Published: 15 April 2020

*Corresponding Author(s): I. Ferreira E-mail: iolandaferreira04@gmail.com

Abstract

Women with a history of hysterectomy due to malignant or premalignant cervical disease are currently submitted to tight surveillance, which consists of vaginal Pap tests for as long as 20 years in the late follow-up period. Nevertheless, published literature has concluded that vaginal Pap screening has a very low detection yield. Also, these recommendations are almost entirely from an era before high-risk HPV (hrHPV) DNA testing. The authors’ aim is to review these women’s current management and share the scarce recommendations available for the management of abnormal vaginal Pap and/or adjunctive hrHPV DNA tests in these patients.

Keywords

Vaginal Pap tests; hrHPV vaginal testing; Follow-up; Hysterectomy; CIN2+.

Cite and Share

I. Ferreira,C. Estevinho,XXX,A. Torgal,C. Carrapatoso,F. Costa. Should we search for high-risk HPV in vaginal vault Pap smear after hysterectomy due to CIN2+?. European Journal of Gynaecological Oncology. 2020. 41(2);157-162.

References

[1] Institute N.C.: “SEER Cancer Stat Facts: Cervical Cancer”. Bethesda. Available at: https://seer.cancer.gov/statfacts/html/ cervix. html

[2] Li Z., Barron S., Hong W., Karunamurthy A., Zhao C.: “Surveillance for recurrent cancers and vaginal epithelial lesions in patients with invasive cervical cancer after hysterectomy: are vaginal cytology and high-risk human papillomavirus testing useful?” Am. J. Clin. Pathol,. 2013, 140, 708.

[3] “Practice Bulletin No. 157: “Cervical Cancer Screening and Prevention”. Obstet. Gynecol., 2016, 127, e1.

[4] Curry S.J., Krist A.H., Owens D.K., Barry M.J., Caughey A.B., Davidson K.W., Force U.P.S.T.: “Screening for Cervical Cancer: US Preventive Services Task Force Recommendation Statement”. JAMA, 2018, 320, 674.

[5] Cancer Council Australia Cervical Cancer Screening Guidelines Working Party: “National Cervical Screening Program: Guidelines for the management of screen-detected abnormalities, screening in specific populations and investigation of abnormal vaginal bleeding”. Sydney: Cancer Council Australia. Available at: https://wiki.cancer.org.au/australiawiki/index.php?oldid= 174048,cited2019Jan31. Available from: https://wiki.cancer.org. au/australia/Guidelines:Cervical_cancer/Screening

[6] Programmes, P. H. E. l. t. N. S.: “NHS Cervical Screening Programme”. In Colposcopy and Programme Management, 3rd ed. March 2016, Vol. NHSCSP, Publication number 20.

[7] Ginecologia, S. P. d., “Consenso sobre infeção por HPV e neoplasia intraepitelial do colo do útero, vulva e vagina”. 2014.

[8] Salani R., Khanna N., Frimer M., Bristow R.E., Chen L.M.: “An update on post-treatment surveillance and diagnosis of recurrence in women with gynecologic malignancies: Society of Gynecologic Oncology (SGO) recommendations”. Gynecol. Oncol., 2017, 146, 3.

[9] Khan M.J., Massad L.S.. Kinney W., Gold M.A., Mayeaux E.J., Darragh T.M., et al.: “A common clinical dilemma: Management of abnormal vaginal cytology and human papillomavirus test results”. Gynecol. Oncol., 2016, 141, 364.

[10] Frega A., Sopracordevole F., Assorgi C., Lombardi D., DE Sanctis V., Catalano A., et al.: “Vaginal intraepithelial neoplasia: a therapeutical dilemma”. Anticancer Res., 2013, 33, 29.

[11] Bansal M., Austin R.M., Zha, C.: “Correlation of histopathologic follow-up findings with vaginal human papillomavirus and lowgrade squamous intraepithelial lesion Papanicolaou test results”. Arch. Pathol. Lab. Med., 2011, 135, 1545.

[12] Sopracordevole F., Barbero M., Clemente N., Fallani M.G., Cattani, P., Agarossi A., et al.: “High-grade vaginal intraepithelial neoplasia and risk of progression to vaginal cancer: a multicentre study of the Italian Society of Colposcopy and Cervico-Vaginal Pathology (SICPCV)”. Eur. Rev. Med. Pharmacol. Sci., 2016, 20, 818.

[13] Schockaert S., Poppe W., Arbyn M., Verguts T., Verguts J.: “Incidence of vaginal intraepithelial neoplasia after hysterectomy for cervical intraepithelial neoplasia: a retrospective study”. Am. J. Obstet. Gynecol., 2008, 199, 113.e1.

[14] Murta E.F., Neves Junior M.A., Sempionato L.R., Costa M.C., Maluf P.J.: “Vaginal intraepithelial neoplasia: clinical-therapeutic analysis of 33 cases”. Arch. Gynecol. Obstet., 2005, 272, 261.

[15] De Vuyst H., Clifford G.M., Nascimento M.C., Madeleine M.M., Franceschi S.: “Prevalence and type distribution of human papillomavirus in carcinoma and intraepithelial neoplasia of the vulva, vagina and anus: a meta-analysis”. Int. J. Cancer, 2009, 124, 1626.

[16] Castle P.E., Rodriguez A.C., Porras C., Herrero R., Schiffman M., Gonzalez P., et al.: “A comparison of cervical and vaginal human papillomavirus”. Sex. Transm. Dis., 2007, 34, 849.

[17] Alemany L., Saunier M., Alvarado-Cabrero I., Quirós B., Salmeron, J., Shin H.R., et al.: “Human papillomavirus DNA prevalence and type distribution in anal carcinomas worldwide”. Int. J. Cancer, 2015, 136, 98.

[18] Castle P.E., Schiffman M., Glass, A.G., Rush B.B., Scott D.R., Wacholder S., et al.: “Human papillomavirus prevalence in women who have and have not undergone hysterectomies”. J. Infect. Dis., 2006, 194, 1702.

[19] “Practice Bulletin No. 168: Cervical Cancer Screening and Prevention”. Obstet. Gynecol., 2016, 128, e111.

[20] Pearce K.F., Haefner H.K., Sarwar S.F., Nolan T.E.: “Cytopathological findings on vaginal Papanicolaou smears after hysterectomy for benign gynecologic disease”. N. Engl. J. Med., 1996, 335, 1559.

[21] Soutter W.P., Sasieni P., Panoskaltsis T.: “Long-term risk of invasive cervical cancer after treatment of squamous cervical intraepithelial neoplasia”. Int. J. Cancer, 2006, 118, 2048.

[22] Gupta S., Sodhani P., Singh V., Sehgal A.: “Role of vault cytology in follow-up of hysterectomized women: results and inferences from a low resource setting”. Diagn. Cytopathol., 2013, 41, 762.

[23] Elit L., Fyles A.W., Devries M.C., Oliver T.K., Fung-Kee-Fung M.:“Follow-up for women after treatment for cervical cancer: a systematic review”. Gynecol. Oncol., 2009, 114, 528.

[24] Song Y.J., Kim J.Y., Lee S.K., Lim H.S., Lim M.C., Seo S.S., et al.: “Persistent human papillomavirus DNA is associated with local recurrence after radiotherapy of uterine cervical cancer”. Int. J. Cancer, 2011, 129, 896.

[25] Elit L., Fyles A.W., Oliver T.K., Devries-Aboud M.C., Fung-KeeFung M.: “Follow-up for women after treatment for cervical cancer”. Curr. Oncol., 2010, 17, 65.

[26] Elit L., Kennedy E.B., Fyles A., Metser U.: “Follow-up for cervical cancer: a Program in Evidence-Based Care systematic review and clinical practice guideline update”. Curr. Oncol., 2016, 23, 109.

[27] Orr J.M., Barnett J.C., Leath C.A.: “Incidence of subsequent abnormal cytology in cervical cancer patients completing five-years of post treatment surveillance without evidence of recurrence”. Gynecol. Oncol., 2011, 122, 501.

[28] de Azevedo A.E., Carneiro F.P., Neto F.F., Bocca A.L., Teixeira L.S., de Queiroz Maurício Filho M.A., et al.: “Association between human papillomavirus infection and cytological abnormalities during early follow-up of invasive cervical cancer”. J. Med. Virol. 2012, 84, 1115.

[29] Badaracco G., Savarese A., Micheli A., Rizzo C., Paolini F., Carosi M., et al.: “Persistence of HPV after radio-chemotherapy in locally advanced cervical cancer”. Oncol. Rep., 2010, 23, 1093.

[30] “FDA approves first human papillomavirus test for primary cervical cancer screening”. Available at: https://wayback.archive-it. org/7993/20170112222903/http://www.fda.gov/NewsEvents/ Newsroom/PressAnnouncements/ucm394773.htm

[31] Gaithersburg M.: “Hybrid Capture 2— HC2 High-Risk HPV DNA Test: A Nucleic Acid Hybridization Microplate Assay With Signal Amplification for the Chemiluminescent Detection of Human Papillomavirus (HPV) Types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 68”. Digene publication L1693 0303. Available at: http://www.accessdata.fda.gov/cdrh_docs/pdf/P890064S009c.pdf

[32] Frega A., French D., Piazze J., Cerekja A., Vetrano G., Moscarini, M.: “Prediction of persistent vaginal intraepithelial neoplasia in previously hysterectomized women by high-risk HPV DNA detection”. Cancer Lett 2007, 249 (2), 235.

[33] England P.H.: “NHS Cervical Screening Programme”. In: Colposcopy and Programme Management, 3rd ed., 2016, March, Vol. NHSCSP Publication number 20.

[34] Berkowitz R.P.: “2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors”. Obstet. Gynecol., 2013, 122, 393.

[35] Koh W.J., Greer B.E., Abu-Rustum N.R., Apte S.M., Campos S.M., Chan J., et al.: Network, N. C. C., “Cervical cancer”. J. Natl. Compr. Canc. Netw., 2013, 11, 320.

[36] Salani R., Backes F.J., Fung M.F., Holschneider C.H., Parker L.P., Bristow R.E., Goff B.A.: “Posttreatment surveillance and diagnosis of recurrence in women with gynecologic malignancies: Society of Gynecologic Oncologists recommendations”. Am. J. Obstet. Gynecol., 2011, 204, 466.

[37] Larsson G. L., Helenius G., Andersson S., Sorbe B., Karlsson M.G.: “Prognostic impact of human papilloma virus (HPV) genotyping and HPV-16 subtyping in vaginal carcinoma”. Gynecol. Oncol., 2013, 129, 406.

[38] Massad L.S., Einstein M.H., Huh W.K., Katki H.A., Kinney W.K., Schiffman M., et al.: Conference, A. C. G.: “2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors”. Obstet. Gynecol., 2013, 121, 829.

Abstracted / indexed in

Science Citation Index Expanded (SciSearch) Created as SCI in 1964, Science Citation Index Expanded now indexes over 9,500 of the world’s most impactful journals across 178 scientific disciplines. More than 53 million records and 1.18 billion cited references date back from 1900 to present.

Biological Abstracts Easily discover critical journal coverage of the life sciences with Biological Abstracts, produced by the Web of Science Group, with topics ranging from botany to microbiology to pharmacology. Including BIOSIS indexing and MeSH terms, specialized indexing in Biological Abstracts helps you to discover more accurate, context-sensitive results.

Google Scholar Google Scholar is a freely accessible web search engine that indexes the full text or metadata of scholarly literature across an array of publishing formats and disciplines.

JournalSeek Genamics JournalSeek is the largest completely categorized database of freely available journal information available on the internet. The database presently contains 39226 titles. Journal information includes the description (aims and scope), journal abbreviation, journal homepage link, subject category and ISSN.

Current Contents - Clinical Medicine Current Contents - Clinical Medicine provides easy access to complete tables of contents, abstracts, bibliographic information and all other significant items in recently published issues from over 1,000 leading journals in clinical medicine.

BIOSIS Previews BIOSIS Previews is an English-language, bibliographic database service, with abstracts and citation indexing. It is part of Clarivate Analytics Web of Science suite. BIOSIS Previews indexes data from 1926 to the present.

Journal Citation Reports/Science Edition Journal Citation Reports/Science Edition aims to evaluate a journal’s value from multiple perspectives including the journal impact factor, descriptive data about a journal’s open access content as well as contributing authors, and provide readers a transparent and publisher-neutral data & statistics information about the journal.

Submission Turnaround Time

Conferences

Top